2022 - Research.com Best Female Scientist Award
Sabina A. Murphy mainly investigates Internal medicine, Cardiology, Myocardial infarction, TIMI and Surgery. Her Internal medicine study frequently draws connections between adjacent fields such as Diabetes mellitus. Her Myocardial infarction study integrates concerns from other disciplines, such as Stroke, Platelet aggregation inhibitor and Hazard ratio.
In her research on the topic of Hazard ratio, Management of acute coronary syndrome is strongly related with Ticagrelor. Her TIMI research incorporates elements of Ischemia, Atorvastatin and Pravastatin. Her Surgery research is multidisciplinary, incorporating elements of Disease and Renal function.
Sabina A. Murphy mostly deals with Internal medicine, Cardiology, TIMI, Myocardial infarction and Acute coronary syndrome. Her work in the fields of Internal medicine, such as Stroke, ST elevation and Percutaneous coronary intervention, intersects with other areas such as In patient. Her study involves Angina, Heart failure, Clopidogrel, Conventional PCI and Coronary artery disease, a branch of Cardiology.
Her TIMI study combines topics from a wide range of disciplines, such as Anesthesia, Vorapaxar, Diabetes mellitus, Fibrinolysis and Atrial fibrillation. Her Myocardial infarction study incorporates themes from Aspirin and Hazard ratio. The concepts of her Acute coronary syndrome study are interwoven with issues in Troponin, Troponin I, Atorvastatin and Pravastatin.
Sabina A. Murphy spends much of her time researching Internal medicine, Cardiology, TIMI, Dapagliflozin and Myocardial infarction. Her work in the fields of Internal medicine, such as Stroke and Hazard ratio, overlaps with other areas such as Evolocumab, In patient and PCSK9. Her biological study spans a wide range of topics, including Albuminuria, Lorcaserin, Weight loss and Atrial fibrillation.
Sabina A. Murphy has included themes like Absolute risk reduction and Heart failure in her Dapagliflozin study. Her study connects Rate ratio and Myocardial infarction. Sabina A. Murphy interconnects Biomarker and Clopidogrel in the investigation of issues within Acute coronary syndrome.
Sabina A. Murphy focuses on Internal medicine, Cardiology, Evolocumab, Myocardial infarction and PCSK9. The Stroke research Sabina A. Murphy does as part of her general Internal medicine study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science. Sabina A. Murphy works in the field of Cardiology, focusing on TIMI in particular.
Her TIMI research incorporates themes from Obesity and Atrial fibrillation. Sabina A. Murphy is interested in Ticagrelor, which is a branch of Myocardial infarction. Sabina A. Murphy has researched Unstable angina in several fields, including Absolute risk reduction and C-reactive protein.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Stephen D. Wiviott;Eugene Braunwald;Carolyn H. McCabe;Gilles Montalescot.
The New England Journal of Medicine (2007)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine;Robert P. Giugliano;Anthony C. Keech;Narimon Honarpour.
The New England Journal of Medicine (2017)
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega;Eugene Braunwald;Stephen D. Wiviott;Jean-Pierre Bassand.
The New England Journal of Medicine (2012)
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Marc P. Bonaca;Deepak L. Bhatt;Marc Cohen;Philippe Gabriel Steg.
The New England Journal of Medicine (2015)
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis
David Preiss;Sreenivasa Rao Kondapally Seshasai;Paul Welsh;Sabina A. Murphy.
Clopidogrel with or without Omeprazole in Coronary Artery Disease
Deepak L. Bhatt;Deepak L. Bhatt;Byron L. Cryer;Charles F. Contant;Marc Cohen.
The New England Journal of Medicine (2010)
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Gilles Montalescot;Stephen D Wiviott;Eugene Braunwald;Sabina A Murphy.
The Lancet (2009)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Stephen D. Wiviott;Dietmar Trenk;Andrew L. Frelinger;Michelle O’Donoghue.
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
Michelle L O'Donoghue;Eugene Braunwald;Elliott M Antman;Sabina A Murphy.
The Lancet (2009)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
Stephen D. Wiviott;Eugene Braunwald;Dominick J. Angiolillo;Simha Meisel.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: